Tags

Type your tag names separated by a space and hit enter

Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin.
Int J Dermatol. 2008 Jan; 47(1):83-6.IJ

Abstract

BACKGROUND

Subacute cutaneous lupus erythematosus (SCLE), a distinct clinical subset of lupus erythematosus, remains a therapeutic challenge, especially in cases resistant to topical and standard systemic therapy. Leflunomide, a novel antirheumatic drug, has shown efficacy in the treatment of systemic lupus erythematosus in pilot studies.

METHODS

We report two patients with SCLE who demonstrated the spectrum of possible clinical responses to leflunomide therapy.

RESULTS

One patient experienced a complete clinical remission of symptoms, whereas the other developed a massive skin reaction which was distinctly related to the commencement of leflunomide therapy.

CONCLUSION

To our knowledge, this is the first time that remission and deterioration of SCLE by leflunomide therapy have been described.

Authors+Show Affiliations

Department of Dermatology, University of Leipzig, Leipzig, Germany. anke.suess@medizin.uni-leipzig.deNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

18173611

Citation

Suess, Anke, and Michael Sticherling. "Leflunomide in Subacute Cutaneous Lupus Erythematosus - Two Sides of a Coin." International Journal of Dermatology, vol. 47, no. 1, 2008, pp. 83-6.
Suess A, Sticherling M. Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin. Int J Dermatol. 2008;47(1):83-6.
Suess, A., & Sticherling, M. (2008). Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin. International Journal of Dermatology, 47(1), 83-6. https://doi.org/10.1111/j.1365-4632.2007.03333.x
Suess A, Sticherling M. Leflunomide in Subacute Cutaneous Lupus Erythematosus - Two Sides of a Coin. Int J Dermatol. 2008;47(1):83-6. PubMed PMID: 18173611.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin. AU - Suess,Anke, AU - Sticherling,Michael, PY - 2008/1/5/pubmed PY - 2008/4/9/medline PY - 2008/1/5/entrez SP - 83 EP - 6 JF - International journal of dermatology JO - Int J Dermatol VL - 47 IS - 1 N2 - BACKGROUND: Subacute cutaneous lupus erythematosus (SCLE), a distinct clinical subset of lupus erythematosus, remains a therapeutic challenge, especially in cases resistant to topical and standard systemic therapy. Leflunomide, a novel antirheumatic drug, has shown efficacy in the treatment of systemic lupus erythematosus in pilot studies. METHODS: We report two patients with SCLE who demonstrated the spectrum of possible clinical responses to leflunomide therapy. RESULTS: One patient experienced a complete clinical remission of symptoms, whereas the other developed a massive skin reaction which was distinctly related to the commencement of leflunomide therapy. CONCLUSION: To our knowledge, this is the first time that remission and deterioration of SCLE by leflunomide therapy have been described. SN - 1365-4632 UR - https://www.unboundmedicine.com/medline/citation/18173611/Leflunomide_in_subacute_cutaneous_lupus_erythematosus___two_sides_of_a_coin_ L2 - https://doi.org/10.1111/j.1365-4632.2007.03333.x DB - PRIME DP - Unbound Medicine ER -